// App-Quantinova.ai

54 : Association of health-related quality of life (HRQOL) variations with biological biomarkers for patients with metastatic castrate-resistant prostate cancer (MCRPC) treated by abiraterone/prednisone combination or prednisone.

Researchers

Presenter

  • Morgan Goujon

Principal Investigators

  • Amelie Anota

  • Alexandre Frontczak

  • Emilie Charton

  • Tristan Maurina

  • Hamadi Almotlak

  • Thierry Nguyen

  • Calcagno Fabien

  • Ulrich Stein

  • Guillaume Mouillet

  • Antoine Thiery-Vuillemin

Medical Centers

  • Department of Medical Oncology, Besancon University Hospital, Besancon, France

  • Quality of Life in Oncology Clinical Research Platform

  • Methodological and Quality of Life in Oncology Unit, University Hospital of Besancon, Besancon, France

  • Department of Urology, University Hospital, Dijon, France

  • Methodology and Quality of Life Unit, Department of Oncology, EA 3181, University Hospital, Besancon, France

  • French National Platform Quality of Life and Cancer, Besancon, France

  • Department of Medical Oncology, Methodological and Quality of Life Unit in Oncology (INSERM UMR 1098), University Hospital, Besançon, France

  • Department of Medical Oncology, INSERM UMR 1098, University Hospital, Besançon, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved